PLSH (Panacea Life Sciences Holdings) ROE %: 0.00% (As of Sep. 2025)


What is Panacea Life Sciences Holdings ROE %?

Panacea Life Sciences Holdings PLSH +3.64% ROE % is 0.00% as of Sep. 2025. The stock has 6 warning signs investors should review. Among 936 Drug Manufacturers companies, Panacea Life Sciences Holdings ranks better than 99.89% on this metric.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Panacea Life Sciences Holdings's annualized net income for the quarter that ended in Sep. 2025 was $-0.74 Mil. Panacea Life Sciences Holdings's average Total Stockholders Equity over the quarter that ended in Sep. 2025 was $-3.09 Mil. Therefore, Panacea Life Sciences Holdings's annualized ROE % for the quarter that ended in Sep. 2025 was N/A%.

The historical rank and industry rank for Panacea Life Sciences Holdings's ROE % or its related term are showing as below:

PLSH' s ROE % Range Over the Past 10 Years
Min: -368.89   Med: -78   Max: -69.25
Current: Negative Equity

During the past 4 years, Panacea Life Sciences Holdings's highest ROE % was -69.25%. The lowest was -368.89%. And the median was -78.00%.

PLSH's ROE % is ranked better than
99.89% of 936 companies
in the Drug Manufacturers industry
Industry Median: 5.865 vs PLSH: Negative Equity

Panacea Life Sciences Holdings  (OTCPK:PLSH) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2025 )
=Net Income/Total Stockholders Equity
=-0.736/-3.087
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-0.736 / 0.2)*(0.2 / 5.405)*(5.405 / -3.087)
=Net Margin %*Asset Turnover*Equity Multiplier
=-368 %*0.037*N/A
=ROA %*Equity Multiplier
=-13.62 %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2025 )
=Net Income/Total Stockholders Equity
=-0.736/-3.087
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-0.736 / -0.736) * (-0.736 / -0.68) * (-0.68 / 0.2) * (0.2 / 5.405) * (5.405 / -3.087)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1.0824 * -340 % * 0.037 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Sep. 2025) net income data. The Revenue data used here is four times the quarterly (Sep. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.

Panacea Life Sciences Holdings ROE % Related Terms

Panacea Life Sciences Holdings ROE % Historical Data

* Premium members only.

The historical data trend for Panacea Life Sciences Holdings's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Panacea Life Sciences Holdings ROE % Chart

Panacea Life Sciences Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23
ROE %
-78.00 -69.25 -368.89 0.00

Panacea Life Sciences Holdings Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 Negative Equity 0.00

PLSH vs NPHC, OWPC, CBDY: ROE % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Panacea Life Sciences Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Panacea Life Sciences Holdings ROE % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Panacea Life Sciences Holdings's ROE % distribution charts can be found below:

* The bar in red indicates where Panacea Life Sciences Holdings's ROE % falls into.


Panacea Life Sciences Holdings ROE % Calculation

Panacea Life Sciences Holdings's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-8.015/( (-2.145+-8.291)/ 2 )
=-8.015/-5.218
=N/A %

Panacea Life Sciences Holdings's annualized ROE % for the quarter that ended in Sep. 2025 is calculated as

ROE %=Net Income (Q: Sep. 2025 )/( (Total Stockholders Equity (Q: Jun. 2025 )+Total Stockholders Equity (Q: Sep. 2025 ))/ count )
=-0.736/( (-9.924+3.75)/ 2 )
=-0.736/-3.087
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2025) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of 0.00% mean?
Panacea Life Sciences Holdings (PLSH) has a ROE % of 0.00% as of Sep. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Panacea Life Sciences Holdings and its competitors. According to the industry distribution chart, Panacea Life Sciences Holdings ranks #1 out of 936 companies in the Drug Manufacturers industry, placing it in the top 0.099999999999994%.
Is Panacea Life Sciences Holdings' ROE % too high?
Panacea Life Sciences Holdings' current ROE % is 0.00%. Based on the distribution chart, Panacea Life Sciences Holdings ranks #1 out of 936 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Panacea Life Sciences Holdings' ROE % compare to NPHC and OWPC?
According to the Drug Manufacturers industry distribution chart, Panacea Life Sciences Holdings ranks #1 out of 936 companies for ROE %. This places Panacea Life Sciences Holdings in the top 0% of its industry — outperforming the majority of peers. The industry median ROE % is 5.87. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 5.87, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Panacea Life Sciences Holdings and its competitors. For the Drug Manufacturers industry, the median ROE % is 5.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Panacea Life Sciences Holdings's current ROE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panacea Life Sciences Holdings stock overvalued right now?
Panacea Life Sciences Holdings (PLSH) has a current ROE % of 0.00%. The current ROE % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Panacea Life Sciences Holdings (PLSH), the current ROE % is 0.00% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Panacea Life Sciences Holdings Business Description

Address 5910 South University Boulevard, C18-193, Greenwood Village, CO, USA, 80121
Panacea Life Sciences Holdings Inc is a holding company organized as a plant-based natural health ingredient and product company, specializing in the development, manufacturing, research, and distribution of products and rapidly growing natural health and wellness market segment for both humans and animals. The company also offers the purest natural remedies within its branded product lines for every aspect of life: PANA Health, PANA Beauty, PANA Sport, PANA Pet, PANA Pure and PANA Life.